KERTYOL PSO
Daily balm
KERTYOL PSO balm is a daily treatment specially designed and adapted for the skin of psoriasis patients.
The innovative active ingredients target the factors involved in the physiopathology of psoriasis. The balm is applied to both the lesions and to the non-lesional skin. This treatment can be used in combination with medicated treatments but also as a relay to space out psoriasis flare-ups.
-
For whom?From age 12Adults
-
Price200ml16,90€400ml25,90€
-
TextureLight fragrance, light texture, non-sticky, does not stain.
Patient relations
-
Application tips
Once a day, in the morning, on the whole body and face, on the lesions and on the unaffected areas.
Do not use on mucous membranes (genital psoriasis).
Not indicated in psoriasis in the folds of the skin (reverse).
-
In combination with the following treatments
Topical treatments (apply at night):- Dermocorticoids (Betamethasone, hydrocortisone, methylprednisolone, clobetasol, fluocinolone)- Association of vitamin D3 and dermocorticoids (calcipotriol + betamethasone)- Vitamin D3 analog (calcipotriol, calcitriol)Systemic treatments: acitretin, Influximab (anti TNF-α), Etanercept(anti TNF-α), Ixecizumab (anti IL-17), phototherapy
Technology of action
Ingredients
Active ingredients:
1st innovative active ingredient from Pierre Fabre biotechnology (technique d’extraction brevetée), CELASTROL®, is of 100% natural origin and produced through the cultivation of plant cells.
Active ingredient derived from an extract of chicory root, Cichorium intybus, rich in oligofructosans.
Polidocanol (or Laureth-9) is a clear syrupy liquid. It is an active ingredient recognized for its antipruginous activity.
Active ingredient that nourishes and promotes the replenishment of the skin's protective hydrolipidic film.
Formula details:
Click on an ingredient type to highlight it in the list
Clinical results and publications
Efficacy results
Pruritus from 8 days (3).
Xerosis from 8 days (4).
Improvement in quality of life (5).
(6).
Tolerance results
Excellent eye tolerance (1).
Excellent tolerance in combination with treatments (2).
Links to clinical results
View all clinical resultsLegal Notice
Clinical study of tolerance and efficacy in 43 adult subjects with mild to moderate psoriasis on the body.
(1) Skin tolerance rated by investigators.
(3) Scoring of pruritus intensity by the subject at D8.
(4) Xerosis score rated by the investigating physician at D8.
(5) PRO patient questionnaire at D8.
(2) Clinical study of tolerance in combination with treatments (topical, phototherapy, oral, biotherapies) in 51 adult subjects with psoriasis on the body.
Skin tolerance rated by investigators.
(6) Hydration kinetics 6 hours after a single application in 22 adult subjects.
Illustrative photographs
D1
D8
D29
Discover the range
Contact us
Would you like to meet a sales representative?
Our medical sales representatives come to your workplace to answer all your questions about our brands and products.
The product concerned may not be available in your country. Please contact your medical sales representative for further information.
Have you noticed any side effects?
The safety and well-being of your patients is our priority. If you notice an unlisted adverse reaction to one of our products, please contact us without delay. We look forward to hearing from you!
Our commitments
Made in France
Product manufactured in our factories in France.
Conscious Care
Pierre Fabre Laboratories brands, including Ducray Dermatological Laboratories, have joined forces and collectively created Conscious Care: a dermo-cosmetic of the future that acts conscientiously towards its entire ecosystem.
Supporting associations
Ducray Dermatological Laboratories support 14 patient associations around the world, with the objective of sharing information on pathologies to improve their management.
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.